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Introduction: The clinical benefit of intensity-modulated radiation 
therapy (IMRT) compared to 3D conformal radiation (3D-RT) has 
not been well established for locally advanced non–small-cell lung 
cancer (NSCLC).
Methods: Using SEER-Medicare, we identified Medicare benefi-
ciaries diagnosed with stage III NSCLC who received potentially 
curative (≥ 25 fractions) thoracic IMRT or 3D-RT from 2002–2009. 
Overall survival and number of hospital days within 90 days of radia-
tion were analyzed using Cox proportional hazard and negative bino-
mial regression models, respectively. Propensity score adjustment 
was used to control for clinical and demographic variables associated 
with outcomes.
Results: IMRT comprised an increasing proportion of conformal 
thoracic radiation for NSCLC, rising from 3.0% in 2002 to 26.8% in 
2009. Use of IMRT varied significantly by year of diagnosis, facility 
type, and geographic region and was more likely to be used among 
patients receiving chemotherapy or with higher comorbidity scores. 
Among patients receiving potentially curative treatment, there was 
no difference in overall survival (propensity adj HR .99, p = 0.83) 
or number of hospital days in the 90 days following radiation start 
(propensity adj HR 1.15, p = 0.23).
Conclusions: When radiation is used to treat locally advanced NSCLC, 
IMRT is increasingly preferred to 3D-RT. However, among patients 
receiving potentially curative radiation there was no significant differ-
ence in overall survival or time spent hospitalized following treatment.
Key Words: Radiation therapy, Lung cancer, Comparative 
effectiveness.
(J Thorac Oncol. 2014;9: 1788–1795)
Lung cancer is the leading cause of cancer death in the United States,1 and about 30% of patients present with 
locally advanced disease.2 Although fewer than 15% survive 
over 5 years, some achieve long-term survival with aggressive 
combination therapies, including radiation therapy.
The adoption of advanced radiation therapy technolo-
gies, such as 3D conformal radiation (3D-RT) and intensity-
modulated radiation therapy (IMRT) have allowed radiation 
oncologists to more accurately target tumor volumes while 
reducing risk of toxicity to surrounding normal tissues. In 
a prior study, we found that adoption of 3D-RT, made pos-
sible by CT-based treatment planning, was associated with 
improved outcomes among patients with stage III non–small-
cell lung cancer (NSCLC) receiving thoracic radiation (TRT).3
IMRT provides a further advance in conformal radia-
tion by varying the intensity of radiation beams to better 
match the shape of a tumor. In 2000, Medicare began to 
reimburse for hospital-based IMRT, which was expanded to 
include freestanding facilities in 2002.4 Although 3D-RT is 
only incrementally more costly than prior technologies, IMRT 
treatments can be significantly more expensive due to greater 
time and expertise necessary for treatment planning, quality 
assurance, and radiation delivery.5
Like 3D-RT, IMRT was initially adopted based on 
superior technical characteristics, despite limited data on its 
clinical effectiveness compared to standard 3D-RT.6 In recent 
years, a growing literature has supported IMRT’s use in pros-
tate and head and neck cancers based on reduction of treat-
ment toxicity, though its effect on disease outcomes is still 
not well established.7–9 Data supporting IMRT for locally 
advanced lung cancers, however, have been more limited.10–12
In the absence of data from randomized controlled trials 
about the efficacy of IMRT, we use data from SEER-Medicare 
to identify factors associated with the use of IMRT versus 
3D-RT and to compare outcomes from treatment, includ-
ing overall survival and number of hospital days following 
treatment.
PATIENTS AND METHODS
Sources of Data
We used data from the National Cancer Institute’s SEER 
cancer registries linked to Medicare claims data. SEER regis-
tries collect data on patient demographics, cancer site, stage, 
histology, and dates of diagnosis and death. Medicare claims, 
both inpatient and outpatient, have been linked to SEER for 
patients of age more than 65 years.13 SEER data for patients 
diagnosed from January 1, 2002, to December 31, 2009, 
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were linked to Medicare claims data from January 1, 2001, to 
December 31, 2010.
Study Cohort
Our cohort included Medicare-enrolled patients of age 
more than 65 years diagnosed with stage III NSCLC from 
2002 to 2009 in a SEER surveillance area, who received TRT 
as a component of their initial treatment. NSCLC had to be 
pathologically confirmed and diagnosed prior to death as the 
first cancer diagnosis. Subjects were continuously enrolled in 
Medicare Parts A and B and not in an HMO from diagnosis 
to death. Staging was based on best available staging infor-
mation recorded by SEER, using AJCC 6th edition schema.14 
Patients with malignant effusion (EOD10 Extent = 72, 79 or 
CS Extension = 72, 79) were excluded. Patients not treated 
with IMRT or 3D-RT, i.e., 2D-RT, were excluded because 
3D-RT had already been widely adopted during the period of 
the study and we wanted to compare IMRT to the “next best” 
technology.
To minimize inadvertent capture of patients receiving 
radiation to extrathoracic sites, we excluded patients with 
any claims associated with International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes indicating development of brain, spine, bone, 
adrenal, or liver metastases (197.7x, 198.30–198.59, 198.7x) 
from diagnosis up to 1 month following the first RT claim.
To account for possible differences in treatment intent 
(i.e., curative versus palliative) between patients receiving 
IMRT and 3D-RT, our analysis focused on patients receiving 
at least 25 fractions of TRT, which corresponds to 45–50 gy in 
1.8–2.0 gy per fraction, consistent with curative intent treat-
ment. Sensitivity analyses were performed using 20 and 30 
fractions as alternate cutpoints.
Definition of Radiation Therapy Variables
Use of TRT as initial treatment was defined as first 
course of RT occurring within 6 months of diagnosis. Patients 
receiving IMRT were identified by the presence of a Current 
Procedural Terminology (CPT) claim code associated with 
delivery of IMRT (77418, 0073T, g0174) and 3D-RT was 
identified based on the presence of a code for three-dimen-
sional reconstruction of tumor volume (77295) and non-IMRT 
external beam radiation delivery (77402–77416).
We calculated the number of treatments or “fractions” 
of TRT delivered by summing the total number of RT deliv-
ery codes after the date of first RT claim. We also identified 
whether patients were treated in a hospital-based outpatient 
facility, a freestanding center, or both based on whether 
Medicare claims for RT delivery were present in files for 
Outpatient claims, Carrier claims, or both, respectively.
Definition of Explanatory Variables
Demographic variables, including age, gender, race, 
marital status, geographic region, urban residence, census 
tract education, and census tract income were obtained from 
SEER data. SEER registries were grouped geographically as 
follows: West (San Francisco, San Jose, Los Angeles, greater 
California, Hawaii, New Mexico, Seattle, Utah), Midwest 
(Detroit, Iowa), South (Atlanta, rural georgia, Kentucky, 
Louisiana), and Northeast (Connecticut, New Jersey). 
Socioeconomic status was estimated by categorizing patients 
in quintiles based on median household income in their cen-
sus track of residence.15 Similarly, patients were categorized in 
education quintiles based on the percentage of persons of age 
more than 25 with some college education residing in their 
census tract. Additional variables were defined according to 
the categories summarized in Table 1.
Clinical variables, including tumor location (upper, 
middle, lower lobe) and AJCC stage (IIIA, IIIB), were identi-
fied from SEER. Treatment variables, including use of che-
motherapy and surgery, were identified from Medicare claims 
using ICD-9-CM, CPT, Health Care Financing Administration 
Common Procedure Coding System (HCPCS), revenue center, 
National Drug Code (NDC), Diagnosis Related groups (DRg), 
and Berenson-Eggers Type of Service (BETOS) codes within 
6 months of diagnosis. We calculated a modified Charlson 
comorbidity index for the 12 months prior to diagnosis using 
Deyo’s implementation16 of the Charlson score17 applied to both 
inpatient and outpatient claims, as suggested by Klabunde.18 In 
addition, we calculated the number of hospital days in the 90 days 
prior to RT as a measure of patient health status at the time of RT. 
Year of diagnosis was grouped into two-year intervals.
Definition of Outcomes
Deaths were defined using Medicare and SEER-
identified death dates through December 31, 2011. Number of 
hospital days in the 90 days following RT start was calculated 
as a measure of treatment-related morbidity. If a hospital stay 
spanned the date of RT start, only days occurring after RT 
start were included.
Statistical Methods
Chi-square and multivariable logistic regression mod-
els were used to compare baseline demographic and clinical 
characteristics between patients who received IMRT versus 
3D-RT. Backward selection was used to eliminate nonsignifi-
cant covariates from the final adjusted models, using a thresh-
old of p < 0.05. Stage and treatment variables were forced into 
the model.
Cox proportional hazards models, controlling for demo-
graphic and clinical variables, were used to compare overall 
survival among IMRT versus 3D-RT patients. Negative bino-
mial regression models were used to compare the number of 
hospital days within 90 days of starting TRT among IMRT 
versus 3D-RT patients.
To account for potential confounding in the survival and 
hospitalization models, propensity scores were generated by 
grouping patients into quintiles based on their propensity to 
receive IMRT, using all demographic and clinical variables 
from Table 1 as predictors.19 Propensity score quintiles were 
then included with all variables in multivariable models in 
order to estimate the effect of IMRT on survival and hospi-
talization rates. Alternate model specifications using propen-
sity-score adjusted quintiles only or with inverse probability 
weights were evaluated and did not significantly influence 
results.20 To adjust for possible unobserved confounders, we 
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tested the use of potential instrumental variables, including 
facility type, but were not able to identify a strong instru-
ment. Therefore an instrumental variable analysis was not 
performed.21,22
P values were two-sided and values less than 0.05 were 
considered statistically significant. SAS software (version 9.2; 
SAS Institute, Cary, NC) was used for all analyses.
RESULTS
We identified 8751 patients of age more than 65 diag-
nosed with stage III NSCLC from 2002 to 2009, who fulfilled 
our inclusion criteria and received TRT within 6 months of 
diagnosis. Of these, 7061 (81%) were treated with either 
IMRT or 3D-RT. Figure 1 summarizes construction of our 
study cohort.
Patient Characteristics and Use 
of IMRT Versus 3D-RT
The median age of patients in our cohort was 74, 56% 
were male and 87% were white. 74% of patients also received 
chemotherapy and 10% had surgical resection within 6 months 
of diagnosis. 66% of patients were treated in hospital-based 
and 34% were treated in freestanding or both facility types. 
Patient characteristics are summarized in Table 1.
Overall, 12.2% of patients diagnosed from 2002 to 2009 
received IMRT, and the proportion receiving IMRT increased 
from 3.0% to 26.8% between 2002 and 2009 (Fig. 2). The 
median survival of patients in our cohort was 404 days, with 
54% surviving 1 year after diagnosis and 29% surviving 2 years. 
Patients spent on average 4.5 days in the hospital in the 90 days 
prior to and 5.1 days in the 90 days following start of TRT.
On multivariable analysis, year of diagnosis was 
strongly associated with IMRT use (overall p < 0.01). We also 
found regional differences in IMRT use, with the highest rates 
TABLE 1.  Cohort Characteristics
n %
Total 7061 100
Demographic characteristics
  Age at diagnosis (median = 74)
   65–69 1965 27.8
   70–74 1947 27.6
   75–79 1693 24
   80+ 1456 20.6
  gender
   Female 3105 44
   Male 3955 56
  Race
   White 6190 87.7
   Black 638 9
   Other 233 3.3
  Marital status
   No 3161 44.8
   Yes 3900 55.2
  SEER region (grouped)
   Northeast 1491 21.1
   South 2346 33.2
   Midwest 953 13.5
   West 2271 32.2
  Living in urban area
   No 839 11.9
   Yes 6222 88.1
  Year of diagnosis
   2002–2003 1253 17.7
   2004–2005 1922 27.2
   2006–2007 1958 27.7
   2008–2009 1928 27.3
  % with some college (census tract quintile)
   1 (lowest) 1362 19.3
   2 1393 19.7
   3 1428 20.2
   4 1441 20.4
   5 (highest) 1435 20.3
  Median income (census tract quintile)
   1 (lowest) 1298 18.4
   2 1395 19.8
   3 1445 20.5
   4 1453 20.6
   5 (highest) 1468 20.8
  Modified Charlson comorbidity scorea
   0 3529 50.0
   1 1998 28.3
   2+ 1534 21.7
Tumor characteristics
  Tumor location
   Upper lobe 4065 57.6
   Middle lobe 271 3.8
   Lower lobe 1758 24.9
   Other 967 13.7
(Continued)
  AJCC Stage (6th edition)
   IIIA 3234 45.8
   IIIB 3827 54.2
Treatment characteristics
  Chemotherapy (within 6 months of diagnosis)
   Yes 5245 74.3
   No 1816 25.7
  Surgical resection (within 6 months of diagnosis)
   Yes 691 9.8
   No 6370 90.2
  Hospital-based versus freestanding RT centerb
   Hospital-based 4652 65.9
   Freestanding RT 
center
2368 33.5
   Both 41 0.6
aMeasured using the Klabunde modification.
bBased on whether Medicare claims for RT delivery were present in files for 
outpatient claims, carrier claims, or both, respectively
TABLE 1. (Continued)
n %
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in the South (12.8%, adj OR: 1.13, 95% CI: 0.90–1.42) and 
West (14.2%, adj OR: 1.25, 95% CI: 1.01–1.56) compared to 
the Northeast (9.9%, referent) and Midwest (9.1%, adj OR: 
0.88, 95% CI: 0.66–1.17) (overall p = 0.03), and higher rates 
in urban versus rural areas (12.5% versus 9.9%, adj OR: 1.52, 
95% CI: 1.17–1.97, p < 0.01). Patients with more comorbidi-
ties were more likely to receive IMRT, 11.3% (referent) versus 
11.7% (adj OR: 1.03, 95% CI: 0.87–1.2) versus 14.7% (adj 
OR: 1.35, 95% CI: 1.13–1.60) for modified Charlson score 0, 
1, and 2+, respectively (p = 0.03). We did not find a significant 
difference in IMRT use between stage IIIA and stage IIIB 
patients (11.8% versus 12.4%, adj OR: 1.11, 95% CI: 0.95–
1.29, p = 0.19). Patients receiving chemotherapy were some-
what more likely to receive IMRT (12.8% versus 10.4%, adj 
OR: 1.24, 95% CI: 1.03–1.48, p = 0.02), though there was 
no difference in IMRT use among patients having surgery 
(11.4% versus 12.2%, adj OR: 0.95, 95% CI: 0.73–1.23, 
p = 0.68). Patients treated at freestanding radiation centers 
were twice as likely to receive IMRT as patients treated at 
hospital-based facilities (17.3% versus 9.5%, adj OR: 2.0, 
95% CI: 1.72–2.33, p < 0.01). Table 2 shows unadjusted and 
adjusted analyses for factors associated with use of IMRT.
Outcomes Among Patients Receiving 
Potentially Curative TRT
Among patients in our cohort, 5417 (77%) received at 
least 25 fractions of TRT, though IMRT patients were more 
likely than 3D-RT patients to receive at least 25 fractions 
(82% versus 76%). Controlling for all demographic and clini-
cal characteristics, we did not observe a significant difference 
in overall survival among patients receiving IMRT versus 
3D-RT (propensity adjusted HR: 0.99, 95% CI .90–1.09, p = 
0.83). Table 3 presents unadjusted, adjusted, and propensity-
adjusted survival analysis results. Sensitivity analyses using 
cutpoints of 20 and 30 fractions to define potentially cura-
tive TRT yielded similar results. However, when the analy-
sis was not limited to patients receiving potentially curative 
TRT, there appeared to be improved survival among patients 
Abbreviations:  NSCLC – non-small cell lung cancer; FFS – fee-for-service; TRT –
thoracic radiation therapy; IMRT – intensity-modulated radiation therapy; 3D-RT – 3D 
conformal radiation therapy
Diagnosed with NSCLC 2002-2009
N= 200,945
Diagnosed prior to death as 1st cancer
N= 178,007
Medicare FFS, Parts A and B
N=102,315
Stage III (AJCC 6th edition)
N= 21,185
TRT delivered within 6 months of diagnosis
N=8751
Medicare-eligible based on diagnosis age 65+
N=146,132
Received conformal RT (IMRT or 3D-RT) 
N=7061
Pathologically confirmed NSCLC
N= 93,494
FIGURE 1.  Study cohort.
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FIGURE 2.  Trends in IMRT use for stage III NSCLC 2002–2009.
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TABLE 2.  Predictors for Use of IMRT vs 3D Conformal Radiation
Predictor 3D RT (N = 6203) IMRT (N = 858) IMRT vs 3D RT IMRT vs 3D RT
Demographic n % n %
Unadjusted OR 
(95% CI) P value
Adjusted OR (95% 
CI) P value
Age at diagnosis, years 0.77
  65–69 1721 87.6% 244 12.4% Ref
  70–74 1715 88.1% 232 11.9% 0.95 (0.79–1.16)
  75–79 1479 87.4% 214 12.6% 1.02 (0.84–1.24)
  80+ 1288 88.5% 168 11.5% 0.92 (0.75–1.13)
gender 0.05
  Female 2701 87.0% 404 13.0% Ref
  Male 3502 88.5% 454 11.5% 0.87 (0.75–1.00)
Race 0.02
  White 5458 88.2% 732 11.8% ref
  Black 553 86.7% 85 13.3% 1.15 (0.90–1.46)
  Other 192 82.4% 41 17.6% 1.59 (1.13–2.25)
Marital status 0.6
  No 2784 88.1% 377 11.9% Ref
  Yes 3419 87.7% 481 12.3% 1.04 (0.90–1.20)
SEER region <.01 0.03
  Northeast 1343 90.1% 148 9.9% Ref Ref
  South 2045 87.2% 301 12.8% 1.34 (1.08–1.65) 1.13 (0.90–1.42)
  Midwest 866 90.9% 87 9.1% 0.91 (0.69–1.20) 0.88 (0.66–1.17)
  West 1949 85.8% 322 14.2% 1.50 (1.22–1.84) 1.25 (1.01–1.56)
Living in urban area 0.03 <.01
  No 756 90.1% 83 9.9% Ref Ref
  Yes 5447 87.5% 775 12.5% 1.30 (1.02–1.65) 1.52 (1.17–1.97)
Year of diagnosis <.01 <.01
  2002–2003 1200 95.8% 53 4.2% Ref Ref
  2004–2005 1810 94.2% 112 5.8% 1.40 (1.00–1.95) 1.35 (0.97–1.89)
  2006–2007 1718 87.7% 240 12.3% 3.16 (2.33–4.30) 3.08 (2.26–4.19)
  2008–2009 1475 76.5% 453 23.5% 6.95 (5.18–9.34) 6.83 (5.07–9.18)
College educated (census tract quintile) 0.25
  1 (lowest) 1182 86.8% 180 13.2% Ref
  2 1230 88.3% 163 11.7% 0.87 (0.69–1.09)
  3 1252 87.7% 176 12.3% 0.92 (0.74–1.15)
  4 1287 89.3% 154 10.7% 0.79 (0.63–0.99)
  5 (highest) 1250 87.1% 185 12.9% 0.97 (0.78–1.21)
Median income (census tract quintile) 0.09
  1 (lowest) 1132) 87.2% 166 12.8% Ref
  2 1223 87.7% 172 12.3% 0.96 (0.76–1.21)
  3 1300 90.0% 145 10.0% 0.76 (0.60–0.96)
  4 1270 87.4% 183 12.6% 0.98 (0.79–1.23)
  5 (highest) 1276 86.9% 192 13.1% 1.03 (0.82–1.28)
Modified Charlson comorbidity score <.01 0.03
  0 3129 88.7% 400 11.3% Ref Ref
  1 1765 88.3% 233 11.7% 1.03 (0.87–1.23) 1.01 (0.84–1.21)
  2+ 1309 85.3% 225 14.7% 1.35 (1.13–1.60) 1.26 (1.05–1.52)
No hospital days in 90 days prior to RT, mean 4 5 1.00 (0.99–1.01)
(Continued)
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receiving IMRT (propensity adj HR: 0.89, 95% CI: 0.84–0.99, 
p = 0.03).
Because common toxicities from TRT, such as radia-
tion pneumonitis, can be diagnoses of exclusion and therefore 
inconsistently diagnosed and coded in claims data, we used the 
number of hospital days in the 90 days following first radia-
tion delivery as an indication of toxicity during and following 
TRT. Though IMRT patients were more likely to have at least 
one hospitalization in the 90 days following treatment (40.5% 
versus 34.2%, p < 0.001), after controlling for demographic 
and clinical characteristics, we did not observe a significant 
difference in number of hospital days in the 90 days follow-
ing start of TRT among patients receiving potentially cura-
tive IMRT versus 3D-RT (3.76 versus 3.4 days, propensity adj 
HR: 1.15, 95% CI: 0.91–1.44, p = 0.23). Table 4 presents the 
full results of the hospital days analysis. Sensitivity analyses 
using cutpoints of 20 and 30 fractions yielded similar results. 
Analyses that were not limited to patients receiving potentially 
curative TRT also did not show a significant difference in hos-
pital days following IMRT versus 3D-RT (5.17 versus 5.06 
days, propensity adj HR: 1.01, 95% CI: 0.85–1.21, p = 0.89). 
Finally, we performed sensitivity analyses removing surgical 
patients from the cohort and did not observe a significant dif-
ference in overall survival (propensity adj HR: 0.99, 95% CI: 
0.90–1.09, p = 0.90) or in number of hospital days following 
for IMRT versus 3D-RT (propensity adj HR: 1.19, 95% CI: 
0.94–1.51, p = 0.15).
DISCUSSION
IMRT Practice Patterns
Among patients receiving TRT for stage III NSCLC we 
found that IMRT was increasingly used since Medicare began 
reimbursing for the procedure, rising from 3.0% to 26.8% 
between 2002 and 2009. We found significant variation in use 
of IMRT by geographic region, and also found higher use in 
urban areas, among patients with greater comorbidities, and 
among patients receiving chemotherapy.
Our finding that patients were twice as likely to receive 
IMRT if treated in a freestanding versus hospital-based facility 
is consistent with prior observations.23 Medicare reimburse-
ment rates for IMRT delivery were higher for freestand-
ing versus hospital-based centers during these years,24 and a 
recent study in prostate cancer patients suggested that differing 
financial incentives could play a role in decisions about radia-
tion technology use.25 An alternative explanation could be that 
hospital-based facilities face greater barriers in adopting new 
technologies and that freestanding centers have greater flex-
ibility in adapting their practices. In the absence of compel-
ling evidence supporting the use of IMRT in lung cancers, it is 
plausible that facilities already adopting IMRT for other can-
cers might also be more likely to use IMRT for lung cancers.
Mell et al. 26,27 previously estimated that 73.2% of radia-
tion oncologists had capabilities for and used IMRT by 2004, 
compared to 32% in 2002. 
Tumor
  Tumor location 0.28
   Upper lobe 3585 88.2% 480 11.8% Ref
   Middle lobe 238 87.8% 33 12.2% 1.04 (0.71–1.51)
   Lower lobe 1522 86.6% 236 13.4% 1.16 (0.98–1.37)
   Other 858 88.7% 109 11.3% 0.95 (0.76–1.18)
  AJCC stage 0.42 0.19
   IIIA 2852 88.2% 382 11.8% Ref Ref
   IIIB 3351 87.6% 476 12.4% 1.06 (0.92–1.22) 1.11 (0.95–1.29)
Initial treatment
  Chemotherapy (within 6 months) 0.01 0.02
   Yes 4575 87.2% 670 12.8% 1.27 (1.07–1.51) 1.24 (1.03–1.48)
   No 1628 89.6% 188 10.4% Ref Ref
  Surgical resection (within 6 months) 0.54 0.68
   Yes 612 88.6% 79 11.4% 0.93 (0.72–1.19) 0.95 (0.73–1.23)
   No 5591 87.8% 779 12.2% Ref Ref
Radiation provider
  Hospital-based versus freestanding Radiation 
center
<.01 <.01
   Hospital-based 4212 90.5% 440 9.5% 0.50 (0.43–0.58) 0.50 (0.43–0.58)
   Freestanding radiation center 1959 82.7% 409 17.3% Ref Ref
   Both 32 78.0% 9 22.0% 1.35 (0.64–2.84) 1.25 (0.58–2.71)
TABLE 2. (Continued)
Predictor 3D RT (N = 6203) IMRT (N = 858) IMRT vs 3D RT IMRT vs 3D RT
Demographic n % n %
Unadjusted OR 
(95% CI) P value
Adjusted OR (95% 
CI) P value
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Comparative Effectiveness of IMRT
For lung cancers, single-institution studies have sug-
gested that IMRT may reduce treatment-related pneumonitis 
and improve overall survival.10–12 However, patients receiving 
IMRT in these studies were typically treated in later years, 
which was not controlled for, so results may be confounded 
by other differences in diagnosis and treatment occurring over 
time. Previous studies of IMRT in lung cancers using SEER-
Medicare data did not find significant differences in pulmo-
nary, cardiac, or esophageal toxicity or in survival outcomes 
between IMRT and 3D-RT.23,28 Our study extends this litera-
ture by including a larger cohort of patients receiving IMRT 
from 2002 to 2009 and by evaluating hospitalizations follow-
ing treatment. It can be challenging to distinguish treatment- 
versus disease-related toxicities from claims-based data, and 
these codes are inconsistently used by providers. To circum-
vent this challenge, we evaluated total number of hospital days 
following treatment.
Among patients receiving at least 25 fractions of TRT, a 
potentially curative treatment course, we did not observe a sig-
nificant difference in overall survival or in number of hospital 
days following start of treatment when comparing IMRT to 
3D-RT. Although stage III NSCLC is often treated with cura-
tive intent TRT, in practice many patients have disease that is 
too extensive to be treated with curative intent. These patients 
may only be candidates for palliative radiation, which is typi-
cally delivered using fewer fractions and with less complex 
techniques. Since IMRT is more time and resource-intensive, 
patients who are not candidate for curative intent radiation 
may be less likely to receive IMRT. This is consistent with 
our observation that a greater proportion of patients receiving 
IMRT were treated with at least 25 fractions. Our finding that 
patients receiving at least 25 fractions spent fewer days in the 
hospital following treatment, compared to the full cohort, also 
supports the view that these patients were more likely to be 
candidates for aggressive treatments. However, another pos-
sible explanation could be that, by reducing toxicity to normal 
tissues, IMRT permits more patients to safely complete their 
planned treatments compared to patients receiving 3D-RT.
There are several important limitations to our analysis. 
First, our data were limited to patients of age more than 65 
living in SEER surveillance areas enrolled in fee-for-service 
Medicare and may not be generalizable to other populations. 
However, because two-thirds of patients diagnosed with 
lung cancer are of age more than 65, and because fee-for-
service Medicare provides insurance coverage for over 95% 
of Americans of age more than 65, our cohort's experience 
should represent the typical patterns of care for NSCLC. 
The SEER-Medicare population has previously been shown 
to be representative of the general population.29,30 In addi-
tion, SEER-Medicare data lack the clinical details necessary 
to identify radiation doses, fields, volumetric and dosimetric 
data, or key clinical parameters such as performance status or 
weight loss. We did not observe a difference in primary tumor 
size between IMRT- and 3D-RT-treated cases among patients 
with recorded data (data not shown), but dosimetry often 
depends more on tumor location and geometry, as well as 
patient anatomy. Though we controlled for demographic and 
clinical characteristics captured in the data source, the poten-
tial for confounding by unmeasured attributes exists. Indeed, 
our observation that IMRT conferred a significant survival 
benefit when analyses were not limited to patients receiving 
a potentially curative treatment course underscores the impor-
tance of selection bias and in considering differing intents of 
treatment when evaluating new radiation technologies.
Although toxicities from radiation can be difficult to 
measure using claims data because of variation in coding prac-
tices, days spent in the hospital provides an objective estimate 
of the most severe toxicities. A downside of this approach is 
that it does not capture lower grade toxicities that do not lead 
to hospitalizations, though other studies in SEER-Medicare 
have not identified differences in claims-based toxicities.23,28 
Though we did not find differences in toxicities requiring 
hospitalization, an abstract from RTOg 06-17, a random-
ized study comparing high versus standard dose radiation 
for locally advanced NSCLC found that, among 357 patients 
completing quality of life questionnaires, those receiving 
IMRT reported less quality of life decline than those receiv-
ing 3D-RT, though provider-reported toxicities did not differ 
substantially. Although patients were not randomized between 
IMRT and 3D-RT, nearly half of patients in each arm received 
IMRT, and these findings suggest that patients could experi-
ence quality of life differences.31
With increasing emphasis on cost containment in health, 
there have been growing pressures on providers to demon-
strate the value of high-cost technologies such as IMRT. Our 
TABLE 3.  Overall Survival Among Patients Treated with 
Potentially Curative (≥ 25 fractions) IMRT vs 3D-RT
Model n
HR for Death 
(IMRT vs 3D 
RT) 95% CI P
5417
Unadjusted 0.95 0.87 to1.04 0.24
Multivariable 
adjusted
0.99 0.90 to 1.09 0.82
Propensity-score 
adjusted
0.99 0.90 to 1.09 0.83
TABLE 4.   Hospital Days in 90 Days Following Potentially 
Curative IMRT vs 3D-RT
Model n
Hospital 
Days in 
90 Days 
Following 
RT, Mean 
(IMRT vs 
3D RT)
Hazard 
Ratio for 
Rate of 
Hospital 
Days 
(IMRT vs 
3D RT) 95% CI P
5417 3.76 vs. 3.40
Unadjusted 1.11 0.89 to 1.38 0.37
Multivariable 
adjusted
1.15 0.92 to 1.44 0.22
Propensity-score 
adjusted
1.15 0.91 to 1.44 0.23
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findings suggest that, although patients treated with IMRT 
had marginally longer survival compared to those treated with 
3D-RT, this was likely due mostly to differences in treatment 
goals. Among patients receiving a potentially curative num-
ber of treatments, there was no clear improvement in overall 
survival, and we also did not observe a significant difference 
in hospital days in the 90 days following start of treatment. 
Though there may not be a significant benefit in survival 
or toxicities from IMRT among patients who can safely be 
treated with curative intent using either IMRT or 3D-RT, 
additional studies may help us to identify subsets of patients 
who do benefit from IMRT, for example those who can only 
achieve potentially curative doses of TRT with IMRT or those 
who may experience significant quality of life benefits.
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